(Q35035150)

5 August 2017

1 reference

title

A review of the effect of atypical antipsychotics on weight (English)

1 reference

5 August 2017

Nasrallah H

1

1 reference

5 August 2017

1 January 2003

1 reference

5 August 2017

Psychoneuroendocrinology

1 reference

5 August 2017

28 Suppl 1

1 reference

5 August 2017

83-96

1 reference

The distribution of body mass index among individuals with and without schizophrenia.

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Body weight gain induced by antipsychotic drugs: mechanisms and management

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Induction of obesity by psychotropic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Weight gain with risperidone.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Serum leptin levels increase rapidly after initiation of clozapine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Weight gain associated with clozapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Determinants of medication compliance in schizophrenia: empirical and clinical findings

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Clozapine and body mass change.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Patient satisfaction and acceptability of long-term treatment with quetiapine

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Treatment of negative and cognitive symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

New atypical antipsychotic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Diabetic ketoacidosis associated with clozapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Weight gain among schizophrenic patients treated with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Clozapine-induced weight gain: prevalence and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Diabetes mellitus in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Clozapine and associated diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

A novel augmentation strategy for treating resistant major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Weight gain associated with neuroleptic medication: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Elevation of prolactin levels by atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900114-2

7 January 2021

10.1016/S0306-4530(02)00114-2

Identifiers

DOI

1 reference

release_qpefxvybefewrpzlmdtilzermm

5 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qpefxvybefewrpzlmdtilzermm

24 November 2022

mapped directly with Wikidata item

PubMed ID

12504074

1 reference

PubMed ID

12504074